IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Xilio Therapeutics Inc (XLO)

CUSIP: 98422T209 | NYSE | 34 institutional holders

Quarters

Q3 2026Q2 2026Q1 2026
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13G/AStemPoint Capital LP628,8669.5%New 5%+ stakeJun 30, 2026No 13F filer matched
13G/AStemPoint Capital LP628,866
9.5% of class · Jun 30, 2026

Institutional Holders — Q3 2026

Geode Capital Management, LLC41,449
0.0% of portfolio›$375.1K
Key FInancial Inc59
0.0% of portfolio›$534
Citigroup Inc1
0.0% of portfolio›$9
StyleTurnoverLocationFiled
Geode Capital Management, LLC
41,449$375.1K0.0%IndexVery LowBoston, MA2026-11-06
Key FInancial Inc
59$5340.0%ETFLowWest Chester, PA2026-11-02
Citigroup Inc
1$90.0%CoreMediumNew York, NY2026-11-04
New 5%+ stake
No 13F filer matched